CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 375 filers reported holding CRISPR THERAPEUTICS AG in Q1 2023. The put-call ratio across all filers is 1.09 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $17,703 | -19.1% | 390 | 0.0% | 0.03% | -12.5% |
| Q2 2023 | $21,895 | +24.1% | 390 | 0.0% | 0.03% | +23.1% |
| Q1 2023 | $17,640 | +11.3% | 390 | 0.0% | 0.03% | +18.2% |
| Q4 2022 | $15,854 | -36.6% | 390 | 0.0% | 0.02% | -24.1% |
| Q3 2022 | $25,000 | -75.0% | 390 | -76.2% | 0.03% | -72.4% |
| Q2 2022 | $100,000 | +33.3% | 1,640 | +37.8% | 0.10% | +47.9% |
| Q1 2022 | $75,000 | -16.7% | 1,190 | 0.0% | 0.07% | +1.4% |
| Q4 2021 | $90,000 | -21.7% | 1,190 | +16.1% | 0.07% | -25.5% |
| Q3 2021 | $115,000 | -30.7% | 1,025 | 0.0% | 0.09% | -26.6% |
| Q2 2010 | $166,000 | – | 1,025 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |